维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="PAVEL ME"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Lanreotide inmetastatic enteropancreatic neuroendocrine tumors 显示文摘	CAPLIN ME PAVEL M fcwiKLA JB	2014	NEngl J Med2014，371，3：	1
2	Practical management of everolimus-related toxicities in patients with ad- vanced solid tumors显示文摘	GRUNWALD V WEIKERT S PAVEL ME	2013	Onkologie2013，36，5：	1
3	Everolimus plus oc- treotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study 显示文摘	Pavel ME Hainsworth JD Baudin E	2005	Lancet2005，378，9808：	1
4	Circulating levels of angio- genic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas 显示文摘	Pavel ME Hassler G Baum U	2005	Clin Endocrinol2005，62，4：	1
5	Lanreotide in metastatic enteropancreatic neuroendocrine tumors显示文摘	Caplin ME Pavel M Cwika JB	2014	N Engl J Med2014，371，3：	1
6	Lanreotide in metastatic enteropancreatic neuroendocrine tumors 显示文摘	Caplin ME Pavel M Cwikta JB	2014	N Engl J Med2014，371，3：	1
7	Lanreotide in metastatic enteropancreatic neuroendocrine tumors显示文摘	Caplin ME Pavel M wik a JB	2014	N Engl J Med2014，371，3：	1
8	Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas显示文摘	Pavel ME Hassler G Baum U	2005	Clin Endocrinol(Oxf)2005，62，4：	1
9	Prevention and treatment of vitamin D deficiency in Dutch psychogeriatric nursing home residents by weekly half-body UVB exposure after showering:apilot study显示文摘	Chel VG Ooms ME Pavel S	2011	Age Ageing2011，40，2：	1
10	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2) : a randomised, placebo-controlled, phase 3 study 显示文摘	Pavel ME Hainsworth JD Baudin E	2011	Lancet2011，378，9808：	1
11	Everolimus plus octreotide longacting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2):a randomised,placebocontrolled,phase 3 study显示文摘	Pavel ME Hainsworth JD Baudin E		0，，9808：	1
12	Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas显示文摘	Pavel ME Hassler G Baum U	2005	Clin Endocrinol (Oxf)2005，62，：	1
13	Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors显示文摘	Pavel ME Wiedenmann B		0，，：	1
14	Circulating levels of angiogenie cytokines can predict tumor progession and prognosis in neuroendocrine carcinomas 显示文摘	Pavel ME Hassler G Baum U	2005	Clin Endoerinol ( Oxf )2005，62，4：	1
15	Pitfall of newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency显示文摘	Rohrer TR Gassmann KF Pavel ME	2003	Bioi Neonate2003，83，1：	1
16	Impact of growth hormone on central nervous activity, vigilance, and tiredness after short-term therapy in growth hormone-deficient adults显示文摘	Pavel ME Lohmann T Hahn EG	2003	Horm Metab Res2003，35，2：	1
17	Lanreotide in metastatic enteropancreatic neuroendocrine tumors显示文摘	Caplin ME Pavel M (C)wik(t)a JB	2014	N Engl J Med2014，371，3：	1
18	Circulating levels of angiogenic cytokines can predict tumor progession and prognosis in neuroendocrine carcinomas显示文摘	Pavel ME Hassler G Baum U	2005	Clin Endocrinol(Oxf)2005，62，4：	1
19	Lanreotide in metastatic enteropancreatic neuroendocrine tumors 显示文摘	Caplin ME Pavel M Ruszniewski P	2014	N Engl J Med2014，371，16：	1
20	Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors 显示文摘	Pavel ME Wiedenman B	2011	Horm Metab Res2011，43，12：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示